A meta-analysis of clinical trials over regimens with or without cetuximab for advanced gastric cancer patients.
CONCLUSION: Adding cetuximab to chemotherapy does not improve OS or DCR compared with chemotherapy alone. Cetuximab-containing combination chemotherapy can reduce the risk of neutropenia.
PMID: 29155518 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Erbitux | Gastric (Stomach) Cancer | Gastroenterology | Study | Toxicology